Allogene Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Allogene Therapeutics, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Allogene Therapeutics has little or no product revenue yet; it used $103m of cash in the twelve months to December 2025. The diluted share count is up 19.1% on a year earlier, which dilutes existing holders.
Our model value for Allogene Therapeutics is under review, so past values are not shown until it is resolved.
Source: 10-K filed March 12, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 12% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Nothing in Allogene Therapeutics, Inc.'s latest figures clears our strength thresholds.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 5, 2026, after the close. Analysts expect revenue of $2220 and EPS of −$0.14 (range −$0.18 to −$0.09) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.58 | +32% | $4m | 0% |
| Next | −$0.62 | −6% | $12m | +216% |
The consensus EPS forecast for the current fiscal year is −4.5% on 90 days ago. In the last 30 days, 2 analysts raised Allogene Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.61 | −$0.68 |
| 60 days ago | −$0.59 | −$0.68 |
| 30 days ago | −$0.59 | −$0.65 |
| 7 days ago | −$0.59 | −$0.65 |
| Now | −$0.58 | −$0.62 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.15 | −$0.13 | +12.2% |
| Mar 2026 | −$0.18 | −$0.18 | 0.0% |
| Dec 2025 | −$0.22 | −$0.17 | +22.5% |
| Sept 2025 | −$0.23 | −$0.19 | +18.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ALLO | −41% | −58% | −49% | −34% | −36% | −20% |
| Industry peers (median) | −35% | −56% | −17% | −28% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ALLO | 58% | 25% | 25% | 33% | 42% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ALLO | −66% | −68% | −72% | −67% | −67% | −64% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 11, 2018: 98% from May 22, 2020 to May 14, 2025. Getting back needed a 5588% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 12, 2026 | −6.6% | +0.9% | +5.2% | −16.0% |
| May 13, 2026 | −7.0% | +1.4% | −17.4% | −17.4% |
| March 12, 2026 | −8.7% | −2.1% | −15.6% | +16.3% |
| November 6, 2025 | +6.3% | −1.0% | +8.1% | +30.6% |
| August 13, 2025 | +3.9% | +0.4% | +2.9% | +9.7% |
| May 13, 2025 | −18.8% | +0.8% | −0.9% | +19.7% |
| March 13, 2025 | −5.8% | +0.7% | −20.9% | −29.6% |
| November 7, 2024 | −4.3% | +1.2% | −23.6% | −29.5% |
| August 7, 2024 | −7.5% | +1.6% | −11.8% | −5.5% |
| May 13, 2024 | +7.2% | +0.5% | −6.2% | −6.9% |
| March 14, 2024 | −4.5% | −0.9% | −10.2% | −27.3% |
| November 2, 2023 | +23.7% | +2.8% | −11.0% | −9.5% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q1 | $147K |
| FY23 Q2 | $105K |
| FY23 Q3 | $100K |
| FY23 Q4 | $95K |
| FY24 Q1 | $87K |
| FY24 Q2 | $65K |
| FY24 Q3 | $43K |
| FY24 Q4 | $22K |
| FY25 Q1 | $0 |
| FY25 Q2 | $0 |
| FY25 Q3 | $0 |
| FY25 Q4 | $0 |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q1 | -99.8% |
| FY23 Q2 | -99.9% |
| FY23 Q3 | -99.9% |
| FY23 Q4 | -39.1% |
| FY24 Q1 | -40.8% |
| FY24 Q2 | -38.1% |
| FY24 Q3 | -57.0% |
| FY24 Q4 | -76.8% |
| FY25 Q1 | -100.0% |
| FY25 Q2 | -100.0% |
| FY25 Q3 | -100.0% |
| FY25 Q4 | -100.0% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY22 Q1 | -299.5% |
| FY22 Q2 | -306.8% |
| FY22 Q3 | -313.3% |
| FY22 Q4 | -215087.2% |
| FY23 Q1 | -241234.0% |
| FY23 Q2 | -341464.8% |
| FY23 Q3 | -339023.0% |
| FY23 Q4 | -344986.3% |
| FY24 Q1 | -342700.0% |
| FY24 Q2 | -444676.9% |
| FY24 Q3 | -692600.0% |
| FY24 Q4 | -1241813.6% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY22 Q1 | -291.1% |
| FY22 Q2 | -280.3% |
| FY22 Q3 | -274.6% |
| FY22 Q4 | -144685.9% |
| FY23 Q1 | -151867.3% |
| FY23 Q2 | -229985.7% |
| FY23 Q3 | -249149.0% |
| FY23 Q4 | -251841.1% |
| FY24 Q1 | -261473.6% |
| FY24 Q2 | -352192.3% |
| FY24 Q3 | -506807.0% |
| FY24 Q4 | -913609.1% |
| Fiscal year | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|---|
| Income | |||||||
| Revenue | 0 | 0 | 114 | 0 | 0 | 0 | 0 |
| EBITDA | −197 | −251 | −170 | −321 | −314 | −260 | −197 |
| Operating income | −202 | −258 | −180 | −336 | −328 | −273 | −209 |
| Net income | −185 | −316 | −182 | −340 | −327 | −258 | −191 |
| Diluted EPS | −$1.83 | −$2.63 | −$1.34 | −$2.38 | −$2.09 | −$1.32 | −$0.87 |
| Growth (year on year) | |||||||
| Revenue | — | — | — | −99.9% | −39.1% | −76.8% | −100.0% |
| Margins | |||||||
| EBITDA margin | — | — | −148.7% | <−999% | <−999% | <−999% | — |
| Operating margin | — | — | −157.9% | <−999% | <−999% | <−999% | — |
| Net margin | — | — | −159.6% | <−999% | <−999% | <−999% | — |
| Free-cash-flow margin | — | — | −180.8% | <−999% | <−999% | <−999% | — |
| Cash flow | |||||||
| Cash from operations | −137 | −115 | −185 | −221 | −238 | −200 | −149 |
| Capital spending | 51 | 66 | 21 | 5 | 2 | 1 | 0 |
| Free cash flow | −188 | −181 | −206 | −226 | −239 | −201 | −150 |
| Stock-based pay | 46 | 65 | 81 | 84 | 66 | 52 | 38 |
| Free cash flow after stock pay | −234 | −246 | −287 | −309 | −305 | −253 | −187 |
| Balance sheet | |||||||
| Cash | 175 | 183 | 173 | 62 | 83 | 75 | 52 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −175 | −183 | −173 | −62 | −83 | −75 | −52 |
| Diluted shares | 101m | 120m | 136m | 143m | 157m | 195m | 221m |
| Quarter | 2024 Q2 Jun 2024 | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| EBITDA | −68 | −69 | −57 | −62 | −54 | −42 | −39 | −44 |
| Operating income | −71 | −72 | −60 | −65 | −57 | −45 | −42 | −47 |
| Net income | −66 | −66 | −60 | −60 | −51 | −41 | −39 | −43 |
| Diluted EPS | −$0.35 | −$0.32 | −$0.28 | −$0.28 | −$0.23 | −$0.19 | −$0.17 | −$0.13 |
| Growth (year on year) | ||||||||
| Revenue | −100.0% | −100.0% | −100.0% | −100.0% | — | — | — | — |
| Margins | ||||||||
| EBITDA margin | — | — | — | — | — | — | — | −954.2% |
| Operating margin | — | — | — | — | — | — | — | <−999% |
| Net margin | — | — | — | — | — | — | — | −919.8% |
| Free-cash-flow margin | — | — | — | — | — | — | — | −692.8% |
| Cash flow | ||||||||
| Cash from operations | −64 | −44 | −37 | −53 | −39 | −30 | −28 | −32 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −64 | −45 | −37 | −53 | −39 | −30 | −28 | −32 |
| Stock-based pay | 14 | 13 | 13 | 12 | 9 | 9 | 8 | 12 |
| Free cash flow after stock pay | −77 | −58 | −50 | −65 | −48 | −39 | −36 | −45 |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $62.7M | 30.1M | 9.6% | ▲ 57.9% |
| Pfizer Inc | $46.9M | 22.0M | 7.2% | 0.0% |
| Frazier Life Sciences Management, L.P. | $46.7M | 22.4M | 7.2% | ▲ 491.2% |
| State Street Corp | $39.6M | 19.0M | 6.1% | ▲ 119.7% |
| Tpg Gp A, LLC | $38.9M | 18.7M | 6.0% | 0.0% |
| Sio Capital Management, LLC | $27.7M | 13.3M | 4.3% | New |
| Primecap Management Co | $27.3M | 13.1M | 4.2% | ▲ 56.6% |
| Vanguard Capital Management LLC | $25.3M | 12.2M | 3.9% | ▲ 75.8% |
| FMR LLC | $25M | 12.0M | 3.8% | ▲ 655.4% |
| Citadel Advisors LLC | $21M | 10.1M | 3.2% | ▲ 48.5% |
| Two Sigma Investments, LP | $16.2M | 7.8M | 2.5% | ▲ 44.8% |
| Geode Capital Management, LLC | $14.7M | 7.0M | 2.2% | ▲ 70.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Allogene Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Parker Geoffrey M. CHIEF FINANCIAL OFFICER | October 21, 2026 | Sell | 36,342 | $1.34 | $48,698 |
| Douglas Earl Martin SVP, General Counsel | August 21, 2026 | Sell | 29,697 | $2.12 | $62,958 |
| Yoshiyama Annie SVP, Finance | April 21, 2026 | Sell | 9,586 | $2.31 | $22,144 |
| Beneski Benjamin Machinas SVP, Chief Technical Officer | March 31, 2026 | Sell | 2,867 | $2.50 | $7,168 |
| Chang David D President and CEO | March 16, 2026 | Sell | 47,763 | $2.47 | $117,975 |
| Beneski Benjamin Machinas SVP, Chief Technical Officer | March 16, 2026 | Sell | 4,835 | $2.47 | $11,942 |
| Beneski Benjamin Machinas SVP, Chief Technical Officer | March 2, 2026 | Sell | 7,132 | $2.60 | $18,543 |
| Roberts Zachary EVP of R&D | February 2, 2026 | Sell | 35,700 | $1.77 | $63,189 |
| Yoshiyama Annie SVP, Finance | February 2, 2026 | Sell | 4,167 | $1.72 | $7,167 |
| Douglas Earl Martin SVP, General Counsel | February 2, 2026 | Sell | 22,900 | $1.76 | $40,304 |
| Parker Geoffrey M. CHIEF FINANCIAL OFFICER | February 2, 2026 | Sell | 24,001 | $1.76 | $42,242 |
| Chang David D President and CEO | February 2, 2026 | Sell | 95,269 | $1.80 | $171,484 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
